PHARMACY MARKET

EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

EyePoint Pharmaceuticals | November 20, 2021

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock. The shares of common stock were sold at a public offering price of $13.75 per share, and the pre-funded warrants were sold at a purchase price of $13.74 per pre-funded warrant, for aggregate gross proceeds of approximately $115.4 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the securities were sold by EyePoint.

Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Cantor acted as passive book-running manager for the offering.

EyePoint intends to use the net proceeds from the offering to advance EYP-1901 into and through Phase 2 clinical trials for wet AMD, DR, and RVO, as well as support its earlier stage pipeline development initiatives, and for general corporate purposes.

The securities described above were offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-258598) previously filed with the Securities and Exchange Commission (SEC) on August 6, 2021 and declared effective by the SEC on August 11, 2021.

The securities were offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC on November 18, 2021.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes stock price volatility and uncertainties relating to the financial markets, the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy, and the impact of general business and economic conditions. More detailed information on these and additional factors that could affect EyePoint’s actual results are described in EyePoint’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


Spotlight

For those who have no idea what CRISPR is all about, the abbreviation means “Clustered Regularly Interspaced Short Palindromic Repeats.” It’s a family of DNA sequences in bacteria. The sequences here play a huge role in fighting bacteria within the body, and if improved, could fight dangerous illnesses as well. This technology for gene-editing treatment has been in the works for quite some time, but could finally come to market due to a company was known as CRISPR Therapeutics.

Spotlight

For those who have no idea what CRISPR is all about, the abbreviation means “Clustered Regularly Interspaced Short Palindromic Repeats.” It’s a family of DNA sequences in bacteria. The sequences here play a huge role in fighting bacteria within the body, and if improved, could fight dangerous illnesses as well. This technology for gene-editing treatment has been in the works for quite some time, but could finally come to market due to a company was known as CRISPR Therapeutics.

Related News

PHARMA TECH

Vivera Receives 3rd U.S. Patent Allowance for ZICOH Drug Delivery Device

Vivera Pharmaceuticals, Inc. | May 26, 2022

Vivera is pleased to announce the allowance of its third U.S. patent for ZICOH™, the Company's high-tech, electronic dose-controlled portfolio of drug delivery devices. The patent allowance from the U.S. Patent and Trademark Office secures ZICOH's rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules, and tablets. ZICOH is an electronic dose-controlled delivery device and technology designed to enable real-time communication through the drug supply chain, from drug manufacturers, distributors, and wholesalers to pharmacists, providers, physicians, caregivers, and patients. The device can be programmed to dispense the medication dosage type, amount, and frequency according to the health care provider's orders to ensure compliance with dispensed prescriptions while also implementing controls to help prevent medication misuse and abuse. Later versions of the device will also implement user authentication features, such as fingerprint authorization and facial recognition, to help prevent prescription drugs from being diverted. Medication reminders are another core feature of ZICOH. These reminders can be programmed into the device by the pharmacist per the physician's orders to alert the patient when it's time to take their medication. This feature can be particularly beneficial for patients who forget to take medications on time or for patients and caregivers who manage multiple medications. "ZICOH is a major innovation in the medical device and technology sectors. This device is going to make it easier than ever for patients to comply with their medication regimens, regardless of how complex they are." Mehdi Hatamian, Ph.D., Chief Scientific Advisor for Vivera This third patent differs from the device's two previously issued patents in that it specifically pertains to the dispensing of tablets, capsules, and pills. The device has already secured its patent rights as a secure, smart liquid and inhaler delivery device with automated dose delivery, measurement, and management. "We are proud of the progress we have made on the development of ZICOH's multiplatform uses and technology," said Paul Edalat, CEO and Chairman of Vivera. "The way that Tesla revolutionized the automotive industry, and the way Apple created a category for smart devices, is what Vivera is doing to the prescription dispensing industry. ZICOH will forever change the way that medications are prescribed and dispensed, and Vivera is reaching the milestones to get there in a fraction of the time projected." Vivera is looking forward to bringing ZICOH to market. The Company has already initiated the device's design and is looking forward to having a working prototype by late summer 2022. About Vivera Pharmaceuticals Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH™, a smart dose-controlled medical device. It also has patents pending on its telemedicine station, MDZone. With multiple divisions, including its pharmaceutical, neurosciences, medical technology, biosciences, and advanced diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.

Read More

PHARMACY MARKET

Sanofi's hopes for rare blood disease candidate sutimlimab on hold after FDA blasts 3rd-party manufacturer

Sanofi | November 17, 2020

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at the contractor's site, the French drugmaker said Friday. A Sanofi spokeswoman declined to specify who the manufacturer cited in the FDA's letter was or what the nature of the deficiencies were. With its application on hold, Sanofi said it would work with its manufacturer and the FDA to resolve the issues in a "timely manner." The drugmaker didn't say how quickly it expected to turn around a new application. The untimely feedback from the FDA dims C1 inhibitor sutimlimab's chances in cold agglutinin disease (CAD), a rare blood disease characterized by anemia, fatigue and other symptoms.

Read More

PHARMA TECH

The IMA Group Announces Acquisition of Redlink, Inc., a Social Security Disability Evaluation Company

IMA Group | January 27, 2022

Extending its service area to seven new states and strengthening it in seven existing markets, The IMA Group (IMA) announced today the acquisition of Redlink, Inc., a regional provider of Social Security Disability evaluations currently operating in the Western United States. The acquisition continues IMA’s long-standing commitment to providing quality Social Security Disability Consultative Examinations (CEs) and positions it to further expand its portfolio of service offerings in rapidly growing markets. The IMA Group is a technology-driven provider of medical and psychological screening and evaluation services with more than 30 years’ experience in returning people to work and productivity. The latest move expands the number of strategically located physicians and other providers specializing in Social Security Administration (SSA) and Disability Determination Services (DDS) evaluations offered by the company. IMA now provides medical and psychological evaluations and related services in more than 35 states, including Washington, Idaho, Nebraska, Utah, Kansas, Wyoming, and Montana. This expansion further enhances IMA’s commitment to serving the needs of rural and under-served communities by bringing more convenient access to local providers and clinics. “In the current economy, the demand for quality outsourced SSA and DDS evaluations is greater than ever. We see tremendous potential for growth in the West, as well as a real need for services we offer. As a long-standing provider of CEs, this acquisition is a natural expansion for our company, and we look forward to serving an ever-broadening client base.” Dr. Mark Weinberger, President & CEO of The IMA Group Financial terms for the two privately held companies were not disclosed. Redlink will continue to operate under its current name to ensure a seamless transition for existing clients, with key leadership, including CEO and founder Jeremy Fenlon, remaining in place. “IMA is a leader in our industry and well-known for its commitment to customer service, which dovetails with our business philosophy,” said Fenlon. “Joining this team will allow Redlink to expand its offerings and continue its long-standing practice of providing top-quality exams overseen by the best professionals in the region. It is a great opportunity for our clients and business.” About The IMA Group For over 30 years, The IMA Group, headquartered in Tarrytown, New York and with offices nationwide, has been dedicated to helping people get back to work and resume productivity. Over the past 10 years, IMA has conducted more than three million evaluations nationwide, utilizing thousands of providers based both at IMA’s 100+ offices as well as independent locations. We provide Government Services clients with medical, psychological and related evaluations, as well as ancillary services. Payer Services supports Commercial Insurers, TPAs, and Corporate clients with Independent Medical Evaluations, Case Management and Occupational Health Services, Fitness for Duty determinations, Pre-Employment examinations and Forensic Drug Testing. The Clinical Research Division offers access to new advances in pharmacology and biotechnology for research subjects, as well as a robust database of interested participants for pharmaceutical manufacturers.

Read More